CLK2 inhibition has been proposed as a potential mechanism to improve autism and neuronal functions in Phelan-McDermid syndrome (PMDS). Herein, the discovery of a very potent indazole CLK inhibitor series and the CLK2 X-ray structure of the most potent analogue are reported. This new indazole series was identified through a biochemical CLK2 Caliper assay screen with 30k compounds selected by an in silico approach. Novel high-resolution X-ray structures of all CLKs, including the first CLK4 X-ray structure, bound to known CLK2 inhibitor tool compounds (e.g., TG003, CX-4945), are also shown and yield insight into inhibitor selectivity in the CLK family. The efficacy of the new CLK2 inhibitors from the indazole series was demonstrated in the mouse brain slice assay, and potential safety concerns were investigated. Genotoxicity findings in the human lymphocyte micronucleus test (MNT) assay are shown by using two structurally different CLK inhibitors to reveal a major concern for pan-CLK inhibition in PMDS.
Balanced pan-class I phosphoinositide
3-kinase inhibition as an
approach to cancer treatment offers the prospect of treating a broad
range of tumor types and/or a way to achieve greater efficacy with
a single inhibitor. Taking buparlisib as the starting point, the balanced
pan-class I PI3K inhibitor 40 (NVP-CLR457) was identified
with what was considered to be a best-in-class profile. Key to the
optimization to achieve this profile was eliminating a microtubule
stabilizing off-target activity, balancing the pan-class I PI3K inhibition
profile, minimizing CNS penetration, and developing an amorphous solid
dispersion formulation. A rationale for the poor tolerability profile
of 40 in a clinical study is discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.